The spirit of collaboration began before the investment. Even during diligence, a mantra of "What can we do to help?” has been evident from the Vibe Bio team.
Evan SussmanCEO & Co-Founder, GranataBio
We are deeply appreciative of our partnership with Vibe Bio. The team went above-and-beyond for us on multiple fronts. Vibe helped us raise an oversubscribed round and has provided unparalleled development expertise. Eigen is thrilled to have a strong cap table to transform cancer treatments for patients worldwide.
Transon Nguyen CEO & Co-Founder, Eigen Therapeutics
Seeking ambitious founders
We invest in exceptional founders seeking exceptional cures. Therapeutic area and modality agnostic, we are not afraid to be early investors to help fund and guide high-potential drug programs through value inflection points. Reach out to us today to start a conversation!
Gain an edge with AI
VibeOne, our AI-powered pipeline analysis platform does more than help us with our own due diligence. We support our portfolio founders with the insights gained from AI, such as risk analysis, competitive benchmarking, or planning. Together, and with AI, we gain an edge over the competition.
Explore our portfolio of breakthrough biotech companies, vetted and backed by Vibe Bio.
Eigen has created an innovative platform to develop a co-therapy approach for the treatment of children with hematological malignancies
Eigen’s approach is to expand the therapeutic window through a unique drug combination that includes a priming therapy to improve the safety and efficacy of existing antigen-directed therapies that can be used to treat a broader cohort of patients. Patients would first be treated with a priming agent to transiently and uniformly upregulate target antigens specifically on cancer cells and not on normal cells – creating an ideal target expression profile that will enable antigen-directed therapy to more effectively eliminate tumor cells while minimizing toxicity.
Granata Bio is a biopharma company focused on women’s health and infertility. While incidence of infertility in the US mirrors that of other developed countries, the cost of US fertility treatment is often borne by the patient, and this presents a significant barrier to treatment.
Founded in 2018, Granata Bio’s model is to identify and in-license strategic medications used in IVF outside of the US for clinical development and commercialization in North America. By doing so, we hope to expand therapeutic options for patients, decrease cost, and increase access to care for every patient seeking fertility treatment on their path to parenthood.